Aiosyn

Aiosyn is a 2020 spin-off from Radboud University Medical Center (Radboudumc) that leverages over 20 years of research experience to build AI-powered pathology software. The company targets the clinical diagnostics and life sciences sectors with certified, workflow-integrated solutions, such as its IVDR-certified mitosis detection tool for breast cancer grading. Its strategy is rooted in close collaboration with pathologists and biopharma partners to co-develop and deploy practical AI tools that improve patient outcomes. Aiosyn is establishing itself through key partnerships and product certifications in the growing digital pathology market.

Modular deep learning platform for analyzing whole slide images in digital pathology, focusing on cancer and kidney disease. Enables deployment of specific AI applications (e.g., mitosis detection, quality control) via cloud or on-premise integration.

Competes with other AI pathology startups (e.g., Paige, PathAI) and digital pathology platform vendors (e.g., Philips, Roche) that are integrating AI capabilities. Differentiation hinges on deep clinical collaboration, modular integration, and IVDR certification for specific diagnostic tasks.